Genetic alterations and biological pathways in human bladder cancer pathogenesis

Knowles, 1995, Molecular genetics of bladder cancer, Br J Urol, 75, 57

Kantor, 1988, Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder, Cancer Res, 48, 3853

Lamm DL, Lamm DA. Superficial Bladder Cancer. Highlights of the ASCO 32nd Annual Meeting, Philadelphia, PA, May 1996.

McCaffrey, 1997, Combined-modality therapy for bladder cancer, Oncol, 11, 18

Sidransky, 1992, Clonal origin of bladder cancer, N Engl J Med, 326, 737, 10.1056/NEJM199203123261104

Minervini, 1996, Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin CB 48-month follow-up, Urol Inter, 56, 234, 10.1159/000282849

Cookson, 1997, The treated natural history of high risk superficial bladder cancer, J Urol, 158, 62, 10.1097/00005392-199707000-00017

Spruck, 1994, Two molecular pathways to transitional cell carcinoma of the bladder, Cancer Res, 54, 784

Reznikoff, 1996, A molecular genetic model of human bladder cancer pathogenesis, Semin Oncol, 23, 571

Gibas, 1997, Cytogenetics of bladder cancer, Cancer Genet Cytogenet, 95, 108, 10.1016/S0165-4608(96)00295-6

Kallioniemi, 1995, Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization, Genes Chromosomes Cancer, 12, 213, 10.1002/gcc.2870120309

Richter, 1997, Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization, Cancer Res, 57, 2860

Hovey, 1998, Genetic alterations in primary bladder cancers and their metastases, Cancer Res, 58, 3555

Habuchi, 1993, Accumulated allelic losses in the development of invasive urothelial cancer, Int J Cancer, 53, 579, 10.1002/ijc.2910530409

Knowles, 1994, Allelotype of human bladder cancer, Cancer Res, 54, 531

Presti, 1991, Molecular genetic alterations in superficial and locally advanced human bladder cancer, Cancer Res, 51, 5405

Li, 1996, Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder, Am J Pathol, 149, 229

Yeager, 1998, Overcoming cellular senescence in human cancer pathogenesis, Genes Dev, 12, 163, 10.1101/gad.12.2.163

Waldman, 1991, Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer, Cancer Res, 51, 3807

Takle, 1996, Deletion mapping implicates two tumor suppressor genes on chromosomes 8p in the development of bladder cancer, Oncogene, 12, 1083

Wagner, 1997, Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer, Am J Path, 151, 753

Sauter, 1995, c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization, Am J Path, 146, 1131

Ruppert, 1993, Evidence for two bladder cancer suppressor loci on human chromosome 9, Cancer Res, 53, 593

Cairns, 1993, Preliminary mapping of the deleted region of chromosome 9 in bladder cancer, Cancer Res, 53, 1230

Miyao, 1993, Role of chromosome 9 in human bladder cancer, Cancer Res, 53, 4066

Orlow, 1994, Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors, Cancer Res, 54, 2848

Habuchi, 1997, A novel candidate tumour suppressor locus at 9q32-q33 in bladder cancer, Hum Mol Genet, 6, 913, 10.1093/hmg/6.6.913

Stadler, 1994, Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer, Cancer Res, 54, 2060

Cairns, 1994, Rates of p16 (MTS1) mutations in primary tumors with 9p Loss, Technical Comments. Science, 265, 415, 10.1126/science.8023167

Cairns, 1995, Frequency of homozygous deletion at p16/CDKN2 in primary human tumours, Nat Genet, 11, 210, 10.1038/ng1095-210

Williamson, 1995, p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer, Hum Mol Genet, 4, 1569, 10.1093/hmg/4.9.1569

Okajima, 1996, Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers, Cancer Letters, 103, 227, 10.1016/0304-3835(96)04225-5

Kagan, 1998, Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer, Oncogene, 16, 909, 10.1038/sj.onc.1201606

Cappellen, 1997, Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder, Oncogene, 14, 3059, 10.1038/sj.onc.1201154

Shaw, 1995, Deletion mapping of chromosome 11 in carcinoma of the bladder, Genes Chromosomes Cancer, 13, 1, 10.1002/gcc.2870130102

Olumi, 1990, Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder, Cancer Res, 50, 7081

Sauter, 1995, Y chromosome loss detected by FISH in bladder cancer, Cancer Genet Cytogenet, 82, 163, 10.1016/0165-4608(95)00030-S

Ishikawa, 1991, Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas, Cancer Res, 51, 5736

Xu, 1993, Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression, Int J Cancer, 53, 781, 10.1002/ijc.2910530513

Serrano, 1993, A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Letters to Nature, Nature, 366, 704, 10.1038/366704a0

Gonzalez-Zulueta, 1995, High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder, J Natl Cancer Inst, 87, 1383, 10.1093/jnci/87.18.1383

Sidransky, 1991, Identification of p53 gene mutations in bladder cancers and urine samples, Science, 252, 706, 10.1126/science.2024123

Panagopoulos, 1996, The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14, Cancer Res, 56, 4871

Groden, 1991, Identification and characterization of the familial adenomatous polyposis coli gene, Cell, 66, 589, 10.1016/0092-8674(81)90021-0

Schreiber-Agus, 1998, Role of Mxi1 in aging organ systems and the regulation of normal and neoplastic growth. Letters to Nature, Nature, 393, 483, 10.1038/31008

Matsuoka, 1995, p57KIP2, a structurally distinct member of the p21CIP1 cdk inhibitor family, is a candidate tumor suppressor gene, Genes Dev, 9, 650, 10.1101/gad.9.6.650

Hahn, 1996, DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1, Science, 271, 350, 10.1126/science.271.5247.350

Hinds, 1994, Function of a human cyclin gene as an oncogene, Proc Natl Acad Sci, 91, 709, 10.1073/pnas.91.2.709

Shin, 1997, Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers, Br J Cancer, 75, 1788, 10.1038/bjc.1997.305

Wright, 1991, Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder, Br J Cancer, 63, 967, 10.1038/bjc.1991.211

Collins, 1998, Positional cloning of ZNF217 and NABC1, Proc Natl Acad Sci, 95, 8703, 10.1073/pnas.95.15.8703

Chow, 1997, Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer, Anticancer Res, 17, 1293

Wang, 1998, Myc activates telomerase, Genes Devel, 12, 1769, 10.1101/gad.12.12.1769

Puthenveettil, 1998, Replicative senescence in human uroepithelial cells, J Urol, in press

Bartkova, 1996, The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis, Cancer Res, 56, 5475

Reznikoff, 1994, Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells, Genes Dev, 8, 2227, 10.1101/gad.8.18.2227

Lacombe, 1996, Analysis of p21WAF1/CIP1 in primary bladder tumors, Oncol Res, 8, 409

Haupt, 1997, mdm2 promotes the rapid degradation of p53, Nature, 387, 296, 10.1038/387296a0

Xiao, 1995, Interaction between the retinoblastoma protein and the oncoprotein mdm2, Nature, 375, 694, 10.1038/375694a0

Sarkis, 1993, Nuclear overexpression of p53 protein in transitional cell bladder carcinoma, J Natl Cancer Inst, 85, 53, 10.1093/jnci/85.1.53

Tsutsumi, 1997, Correlation of allelic loss of the p53 gene and tumor grade, stage, and malignant progression in bladder cancer, Inter J Urol, 41, 74, 10.1111/j.1442-2042.1997.tb00144.x

Vet, 1996, Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer, Clin Cancer Res, 2, 1055

Casetta, 1997, p53 expression compared with other prognostic factors in OMS Grade-1 Stage-Ta transitional cell carcinoma of the bladder, Eur Urol, 32, 229, 10.1159/000480864

Burkhard, 1997, Immunohistochemical determination of p53 overexpression, Urol Res, 25, S31, 10.1007/BF00942045

Underwood, 1996, Overexpression of p53 protein and its significance for recurrent progressive bladder tumours, Br J Urol, 77, 659, 10.1046/j.1464-410X.1996.09386.x

Lipponen, 1995, Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer, J Cancer Res Clin Oncol, 121, 44, 10.1007/BF01202728

Logothetis, 1992, Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer, J Natl Cancer Inst, 84, 1256, 10.1093/jnci/84.16.1256

Grossman, 1998, p53 and RB expression predict progression in T1 bladder cancer, Clin Cancer Res, 4, 829

Cordon-Cardo, 1997, Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors, Cancer Res, 57, 1217

Cote, 1998, Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53, Cancer Res, 58, 1090

Imai, 1995, Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder, Br J Cancer, 71, 69, 10.1038/bjc.1995.14

Sauter, 1993, Heterogeneity of erbB-2 gene amplification in bladder cancer, Cancer Res, 53, 2199

Wagner, 1995, Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder, Hum Pathol, 26, 970, 10.1016/0046-8177(95)90086-1

Moch, 1994, p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer, Hum Pathol, 25, 1346, 10.1016/0046-8177(94)90096-5

Yeager, 1995, Increased p16 levels correlate with pRb alterations in human urothelial cells, Cancer Res, 55, 493

Bookland, 1992, Induction of thioguanine-resistant mutations in human uroepithelial cells by 4-aminobiphenyl and its N-hydroxy derivatives, Cancer Res, 52, 1615

Bookland, 1992, Tumorigenic transformation and neoplastic progression of human uroepithelial cells after exposure in vitro to 4-aminobiphenyl or its metabolites, Cancer Res, 52, 1606

Christian, 1987, Characterization of human uroepithelial cells immortalized in vitro by simian virus 40, Cancer Res, 47, 6066

Kao, 1992, Losses of 3p, 11p, and 13q in EJ/ras-transformable simian virus 40-immortalized human uroepithelial cells, Genes Chromosomes Cancer, 4, 158, 10.1002/gcc.2870040210

Belair, 1996, Immortalization of human uroepithelial cells by human papillomavirus 16 E6 or E7, Rad Onc Invest, 3, 368, 10.1002/roi.2970030623

Savelieva, 1997, 20q gain associates with immortalization, Oncogene, 14, 551, 10.1038/sj.onc.1200868

Bates, 1998, p14ARF links the tumour suppressors RB and p53, Science, 395, 124

Palmero, 1998, p19ARF links the tumour suppressor p53 to RAS, Science, 395, 125

Klingelhutz, 1991, Allelic 3p deletions in high-grade carcinomas after transformation in vitro of human uroepithelial cells, Genes Chromosomes Cancer, 3, 346, 10.1002/gcc.2870030505

Reznikoff, 1988, Neoplastic transformation of SV40-immortalized human urinary tract epithelial cells by in vitro exposure to 3-methylcholanthrene, Carcinogenesis, 9, 1427, 10.1093/carcin/9.8.1427

Pazzaglia, 1994, In vitro radiation-induced neoplastic progression of low-grade uroepithelial tumors, Rad Research, 138, 86, 10.2307/3578850

Christian, 1990, EJ/ras neoplastic transformation of simian virus 40-immortalized human uroepithelial cells, Cancer Res, 50, 4779

Pratt, 1992, Neoplastic progression by EJ/ras at different steps of transformation in vitro of human uroepithelial cells, Cancer Res, 52, 688

Wu, 1991, Nonrandom chromosome losses in stepwise neoplastic transformation in vitro of human uroepithelial cells, Cancer Res, 51, 3323

Newton, 1994, Addressing the significance of chromosome-loss data, Stat Med, 13, 839, 10.1002/sim.4780130805

Kao, 1993, Role of SV40 T antigen binding to pRB and p53 in multistep transformation in vitro of human uroepithelial cells, Carcinogenesis, 14, 2297, 10.1093/carcin/14.11.2297

Klingelhutz, 1991, Nonrandom chromosome losses in tumorigenic revertants of hybrids between isogenic immortal and neoplastic human uroepithelial cells, Somatic Cell Mol Genetics, 17, 551, 10.1007/BF01233620

Pratt, 1992, Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids, Cancer Genet Cytogenet, 59, 180, 10.1016/0165-4608(92)90213-R

Belair, 1997, Telomerase activity, Proc Natl Acad Sci USA, 94, 13677, 10.1073/pnas.94.25.13677

Kinoshita, 1997, Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer, J Natl Cancer Inst, 89, 724, 10.1093/jnci/89.10.724